1. Home
  2. WHG vs VTVT Comparison

WHG vs VTVT Comparison

Compare WHG & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Westwood Holdings Group Inc

WHG

Westwood Holdings Group Inc

HOLD

Current Price

$20.34

Market Cap

156.2M

Sector

Finance

ML Signal

HOLD

Logo vTv Therapeutics Inc.

VTVT

vTv Therapeutics Inc.

HOLD

Current Price

$34.99

Market Cap

148.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WHG
VTVT
Founded
1983
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
156.2M
148.7M
IPO Year
2002
2015

Fundamental Metrics

Financial Performance
Metric
WHG
VTVT
Price
$20.34
$34.99
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$53.00
AVG Volume (30 Days)
31.4K
48.5K
Earning Date
04-30-2026
05-07-2026
Dividend Yield
3.58%
N/A
EPS Growth
203.85
N/A
EPS
0.09
N/A
Revenue
$97,762,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$226.00
N/A
Revenue Growth
3.21
N/A
52 Week Low
$14.70
$14.00
52 Week High
$20.97
$44.00

Technical Indicators

Market Signals
Indicator
WHG
VTVT
Relative Strength Index (RSI) 59.88 48.51
Support Level $15.78 $34.02
Resistance Level $20.97 $40.36
Average True Range (ATR) 1.17 2.65
MACD 0.08 -0.08
Stochastic Oscillator 70.76 31.41

Price Performance

Historical Comparison
WHG
VTVT

About WHG Westwood Holdings Group Inc

Westwood Holdings Group Inc manages investment assets and provides services for clients through subsidiaries. It operates its business through the Advisory and Trust segments. Its Advisory segment provides investment advisory services to corporate retirement plans, public retirement plans, endowments, foundations, individuals and the Westwood Funds, as well as investment sub-advisory services to mutual funds and its trust segment. The Trust segment offers trust and custodial services to its clients and its advisory segment sponsors common trust funds to institutions and high net-worth individuals. It generates maximum revenue from the Advisory segment. Geographically, it derives a majority of its revenue from the United States, and also has its presence in Canada.

About VTVT vTv Therapeutics Inc.

vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.

Share on Social Networks: